Treatment of CML using IFN-α: Impact on quality of life

Hematology Journal

Volumn 4, Issue 4, 2003, Pages 253-262

  Homewood, Janis ^a   Watson, Maggie ^a,b   Richards, Sue M ^c   Halsey, Jim ^c   Shepherd, Pat C A ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; CML; IFN ; Interferon alpha; Quality of life

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; IMATINIB; TIOGUANINE;

ABDOMINAL DISCOMFORT; ADULT; AGE; AGED; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EMOTIONAL DISORDER; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; GENDER; HAIR DISEASE; HEARING LOSS; HUMAN; INDIGESTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; PAIN; PREVALENCE; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SKIN DISEASE; SNEEZING; SOCIAL INTERACTION; UNITED KINGDOM; WEIGHT GAIN;

COGNITION; CROSS-SECTIONAL STUDIES; DRUG EVALUATION; DYSPNEA; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PAIN; QUALITY OF LIFE; QUESTIONNAIRES; RANDOM ALLOCATION; SELF ASSESSMENT (PSYCHOLOGY); SEXUAL BEHAVIOR; SOCIAL BEHAVIOR;

EID: 0042524665     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200251     Document Type: Article

References (34)

1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Talpaz M, McCredie K, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689-692.
3. Talpaz M, Kantarjian HM, McCredie KB, Trujillo J, Keating MJ, Gutterman J. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065-1069.
4. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.
5. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-538.
6. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616-1620.
7. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392-1397.
8. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984 (see comments).
9. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-150.
10. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
11. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
12. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.
13. Dusheiko G. Side effects of alpha IFN in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1): 112S-121S.
14. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 1998; 91: 2713-2721.
15. Dalekos GN, Christodoulou D, Kistis KG, Zervou E, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side-effects during alpha-IFN therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10: 933-939.
16. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of IFN-alpha therapy. Semin Oncol 1998; 25(1 Suppl 1): 39-47.
17. Shepherd P, Richards S, Allan N on behalf of the MRC Adult Leukaemia Working Party. Interferon therapy in CML: compliance and side effects in a randomized trial, MRC CML 3. Haematologica 2000; 85(Suppl, June 2000): 24.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organisation for Research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
19. Zittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1997; 20: 307-315.
20. Busch NE, Haberman M, Donaldson G, Sullivan KM. Quality of Life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 1995; 40: 479-490.
21. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG, Goldstone AH et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999; 86: 1231-1239.
22. Shepherd P, Harrison G, Richards S on behalf of the MRC Adult Leukaemia Working Party. Quality of life in patients receiving high or low dose interferon alpha therapy in chronic myeloid leukaemia (CML): a report from the MRC CML V Randomised Trial. Br J Haematol 2002; 117(Suppl 1): 72 (abstract 43).
23. Fayers P, Weeden S, Curran D. EORTC QLQ-C30 Reference Values. EORTC Quality of Life Study Group: Brussels, 1998.
24. Fischer T, Talpaz M. Biology of interferon in chronic myeloid leukaemia. In: Carella A, Daley G, Eaves C, Goldman J, Hehlmann R (eds). Biology and Treatment. Martin Dunitz: London. 2001.
25. Shepherd P. Interferon-a dosage regimens in chronic myeloid leukaemia. In: Carella A, Daley G, Eaves C, Goldman J, Hehlmann R (eds). Biology and Treatment. Martin Dunitz: London. 2001.
26. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R et al. Sarcoidosis associated with IFN-alpha therapy for chronic hepatitis C. J Hepatol 1998; 28: 1058-1063.
27. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125: 541-548 (see comments).
28. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 2673-2682.
29. Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 1998; 9: 389-396.
30. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Eng J Med 2002; 346: 645-652.
31. Druker BJ for the IRIS (International Randomized IFN vs STI571) Study Group. STI571(Gleevec/Glivec, imatinib versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. Proc Am Soc Clin Onc 2002; 21: 1a.
32. Hann EA. The quality of life of patients with chronic phase chronic myeloid leukaemia in the IRIS study of interferon-alpha plua Ara-C vs Imatinimb (STI571, Glivec). Hematol J 2002; 3(Suppl 1): 300 (abstract 1014).
33. Hann E, Sorensen M, Hudgens S, Glendinning G, IRIS Study Group. Quality of life of patients with chronic phase chronic myeloid leukaemia in the IRIS study of interferon-alpha plus Ara-C vs imatinib (STI571, Glivec®, Gleevec™). Blood 2002; 100: 94a (abstract 346).
34. O'Brien S, Vallance S, Craddock C, Holyoake T, Goldman J, the UK PISCES Group. PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood 2001; 98: 846a.